Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
This report presents an accurate portrayal of all the factors that influence the global postmenopausal vaginal atrophy treatment and drug market. It studies the relevant factors that surround this market with the intention of providing its readers influential guidance. The report considers all the factors that have influenced the global postmenopausal vaginal atrophy treatment and drug market so far and predicts that ones that will influence it in the near future. To establish the future prospects of this market, highly competent methodologies have been implemented. Through these procedures, it is deduced where the global postmenopausal vaginal atrophy treatment and drug market is headed.
The global postmenopausal vaginal atrophy treatment and drug market is segmented based on the vaginal atrophy epidemiology in relation to different regions, age, prevalence, and severity.
The report thus covers all grounds of the global postmenopausal vaginal atrophy treatment and drug market, including drivers, restraints, and market trends. The analysis also accounts for the most recent drugs and technologies that have been devised in this market. The report employs the Porter’s Five Forces model analysis, along with a SWOT analysis of the major market players. There is a detailed explanation of each macro and micro factor that is essential for all the players in the market, whether existing ones or new entrants.
Overview of the Global Postmenopausal Vaginal Atrophy Treatment and Drug Market
Most of the recent developments in the global postmenopausal vaginal atrophy treatment and drug market have been highly positive. The growth of this market is attributed to the growing percentage of the geriatric demographic, cultural changes in the perception of sexuality and its medical complications, and the launch of major non-estrogen-based drugs. These drugs include Osphena and Vaginorm. Another factor promoting the growth of the global postmenopausal vaginal atrophy treatment and drug market is the improvement of the Affordable Care Act to accommodate this medical condition.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1994
On the other hand, the market is being restrained by the influx of a large number of generic drugs that are priced much lower than their patented competitors. This has happened due to the patent expiration of several major drugs and through multiple licensing agreements. Some of the major branded drugs for vaginal atrophy in the market today are Premarin, Estrace, Estring, Vagifem, and Colpotrophine.
Companies mentioned in the research report
The key players in the global postmenopausal vaginal atrophy treatment and drug market are Bristol Myers, Novartis, Pfizer, Merck, and Mylan.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453